ZMapp treatment for Ebola

The Ebola Virus epidemic that began in March in West Africa now involves patients in Sierra Leone, Liberia, Guinea, and Nigeria. Of the 1,603 cases, there have been 887 deaths, giving a mortality rate of 55 percent. The two Americans who acquired the infection in Liberia are showing remarkable response to ZMapp, a new experimental drug produced by Mapp Biopharmaceutical.  ZMapp is a collection of monoclonal antibioties generated in mice that were exposed to fragments of Ebola virus. The medicine had never been used in humans. Trials in monkeys had been limited but showed promise.